Opus Genetics, Inc. revenue
Opus Genetics, Inc.'s revenue was $14.2m in fiscal 2025, up 29.1% on the year before. Since fiscal 2019 ($3.0m) it has grown at a compound 29.6% a year. Over the last twelve months it was $9.9m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 40 | 19 | 11 | 14 | 10 |
| Growth on the year before | — | — | — | — | — | — | −100.0% | — | +>999% | −52.2% | −42.3% | +29.1% | — |
| Gross profit | −0 | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Opus Genetics, Inc. | $9.9m | -36.1% | -39.8% |
| Caribou Biosciences, Inc. | $10.0m | 10.0% | -11.0% |
| Relay Therapeutics, Inc. | $10.3m | 23.9% | 122.3% |
| Mindwalk Holdings Corp. | $11.3m | 47.8% | — |
| Apollomics Inc. | $8.5m | — | — |
| Surrozen, Inc. | $11.5m | -8.8% | — |
Compare with peers
- Caribou Biosciences, Inc. revenue
- Relay Therapeutics, Inc. revenue
- Mindwalk Holdings Corp. revenue
- Apollomics Inc. revenue
- Surrozen, Inc. revenue
Head to head: CRBU vs IRDIRD vs RLAYHYFT vs IRD
More: Biotechnology stocks compared, Health Care sector, rankings of US companies